csirt@kutim:~/threat-intel/cve/CVE-2022-20695

Katalog CVE

CVSS 10.0 · Critical EPSS 19,8%

Kerentanan Incorrect Implementation of Authentication Algorithm pada cisco wireless lan controller 8.10.151.0, cisco wireless lan controller 8.10.162.0. Skor CVSS 3.1 10.0 (Critical) menurut NVD.

Deskripsi (NVD)

A vulnerability in the authentication functionality of Cisco Wireless LAN Controller (WLC) Software could allow an unauthenticated, remote attacker to bypass authentication controls and log in to the device through the management interface This vulnerability is due to the improper implementation of the password validation algorithm. An attacker could exploit this vulnerability by logging in to an affected device with crafted credentials. A successful exploit could allow the attacker to bypass authentication and log in to the device as an administrator. The attacker could obtain privileges that are the same level as an administrative user but it depends on the crafted credentials. Note: This vulnerability exists because of a non-default device configuration that must be present for it to be exploitable. For details about the vulnerable configuration, see the Vulnerable Products section of this advisory.

Rincian

Terbit di NVD
15 April 2022
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
10.0 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-303: Incorrect Implementation of Authentication Algorithm
CWE-287: Improper Authentication
EPSS (30 hari)
19,8% peluang dieksploitasi; lebih tinggi dari 97,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco wireless lan controller 8.10.151.0 Semua versi
cisco wireless lan controller 8.10.162.0 Semua versi

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.